152 related articles for article (PubMed ID: 32682367)
21. CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis.
Tran L; Huitema AD; van Rijswijk MH; Dinant HJ; Baars JW; Beijnen JH; Vogel WV
Hum Antibodies; 2011; 20(1-2):29-35. PubMed ID: 21558621
[TBL] [Abstract][Full Text] [Related]
22. Population pharmacokinetic and exposure-response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia.
Gibiansky E; Gibiansky L; Chavanne C; Frey N; Jamois C
CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):914-927. PubMed ID: 34110098
[TBL] [Abstract][Full Text] [Related]
23. Effect of Number of Bifunctional Chelating Agents on the Pharmacokinetics and Immunoreactivity of 177Lu-labeled Rituximab: A Systemic Study.
Guleria M; Das T; Kumar C; Sharma R; Amirdhanayagam J; Sarma HD; Dash A
Anticancer Agents Med Chem; 2018; 18(1):146-153. PubMed ID: 28745238
[TBL] [Abstract][Full Text] [Related]
24. 17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia.
Bagacean C; Tempescul A; Ternant D; Banet A; Douet-Guilbert N; Bordron A; Bendaoud B; Saad H; Zdrenghea M; Berthou C; Paintaud G; Renaudineau Y
J Immunother Cancer; 2019 Jan; 7(1):22. PubMed ID: 30696487
[TBL] [Abstract][Full Text] [Related]
25. Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases.
Kattah AG; Fervenza FC; Roccatello D
Autoimmun Rev; 2013 Jun; 12(8):854-9. PubMed ID: 23000633
[TBL] [Abstract][Full Text] [Related]
26. Clinical Pharmacokinetic and Pharmacodynamic Considerations in Treating Non-Hodgkin Lymphoma.
Blosser N; Jupp J; Yau P; Stewart D
Clin Pharmacokinet; 2020 Jan; 59(1):7-23. PubMed ID: 31385204
[TBL] [Abstract][Full Text] [Related]
27. Comparative assessment of clinical response in patients with rheumatoid arthritis between PF-05280586, a proposed rituximab biosimilar, and rituximab.
Williams JH; Hutmacher MM; Zierhut ML; Becker JC; Gumbiner B; Spencer-Green G; Melia LA; Liao KH; Suster M; Yin D; Li R; Meng X
Br J Clin Pharmacol; 2016 Dec; 82(6):1568-1579. PubMed ID: 27530379
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20
Jiang B; Ke X; Zhang Q; Xu W; Su H; Huang J; Zhang M; Wang H; Jin C; Zhu J; Liu L; Cai Z; Zhao X; Zhou J; Zhang X; Liu J; Zhou H; Yu J; Sun X; Qi J; Qiu L
Sci Rep; 2020 Jul; 10(1):11676. PubMed ID: 32669656
[TBL] [Abstract][Full Text] [Related]
29. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.
Breedveld F; Agarwal S; Yin M; Ren S; Li NF; Shaw TM; Davies BE
J Clin Pharmacol; 2007 Sep; 47(9):1119-28. PubMed ID: 17766699
[TBL] [Abstract][Full Text] [Related]
30. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.
Cohen S; Clowse M; Pardo P; Bhattacharya I; Menon S; Gourley I; Diehl A
Clin Ther; 2016 Jun; 38(6):1417-1434.e2. PubMed ID: 27112532
[TBL] [Abstract][Full Text] [Related]
31. The pharmacokinetics of ¹²⁴I-rituximab in patients with rheumatoid arthritis.
Tran L; Vogel WV; Sinaasappel M; Muller S; Baars JW; van Rijswijk M; Dinant HJ; Beijnen JH; Huitema AD
Hum Antibodies; 2011; 20(1-2):7-14. PubMed ID: 21558619
[TBL] [Abstract][Full Text] [Related]
32. B-cell imaging with zirconium-89 labelled rituximab PET-CT at baseline is associated with therapeutic response 24 weeks after initiation of rituximab treatment in rheumatoid arthritis patients.
Bruijnen S; Tsang-A-Sjoe M; Raterman H; Ramwadhdoebe T; Vugts D; van Dongen G; Huisman M; Hoekstra O; Tak PP; Voskuyl A; van der Laken C
Arthritis Res Ther; 2016 Nov; 18(1):266. PubMed ID: 27863504
[TBL] [Abstract][Full Text] [Related]
33. CD4+ count-dependent concentration-effect relationship of rituximab in rheumatoid arthritis.
Bensalem A; Mulleman D; Thibault G; Azzopardi N; Goupille P; Paintaud G; Ternant D
Br J Clin Pharmacol; 2019 Dec; 85(12):2747-2758. PubMed ID: 31454097
[TBL] [Abstract][Full Text] [Related]
34. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
Lee S; Lee H; Kim E
BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
[TBL] [Abstract][Full Text] [Related]
35. Repeat cycles of rituximab on clinical relapse in ANCA-associated vasculitis: identifying B cell biomarkers for relapse to guide retreatment decisions.
Md Yusof MY; Vital EM; Das S; Dass S; Arumugakani G; Savic S; Rawstron AC; Emery P
Ann Rheum Dis; 2015 Sep; 74(9):1734-8. PubMed ID: 25854586
[TBL] [Abstract][Full Text] [Related]
36. Comparative assessment of pharmacokinetics, and pharmacodynamics between RTXM83™, a rituximab biosimilar, and rituximab in diffuse large B-cell lymphoma patients: a population PK model approach.
Candelaria M; Gonzalez D; Fernández Gómez FJ; Paravisini A; Del Campo García A; Pérez L; Miguel-Lillo B; Millán S
Cancer Chemother Pharmacol; 2018 Mar; 81(3):515-527. PubMed ID: 29362903
[TBL] [Abstract][Full Text] [Related]
37. Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
Wallace ZS; Fu X; Liao K; Kallenberg CGM; Langford CA; Merkel PA; Monach P; Seo P; Specks U; Spiera R; St Clair EW; Zhang Y; Choi H; Stone JH
Arthritis Rheumatol; 2019 Nov; 71(11):1879-1887. PubMed ID: 31162829
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis.
Cornec D; Kabat BF; Mills JR; Cheu M; Hummel AM; Schroeder DR; Cascino MD; Brunetta P; Murray DL; Snyder MR; Fervenza F; Hoffman GS; Kallenberg CGM; Langford CA; Merkel PA; Monach PA; Seo P; Spiera RF; St Clair EW; Stone JH; Barnidge DR; Specks U
Rheumatology (Oxford); 2018 Apr; 57(4):639-650. PubMed ID: 29340623
[TBL] [Abstract][Full Text] [Related]
39. Rituximab biosimilar CT-P10 for the treatment of rheumatoid arthritis.
Jung JY; Kim JW; Kim HA; Suh CH
Expert Opin Biol Ther; 2019 Oct; 19(10):979-986. PubMed ID: 31498682
[No Abstract] [Full Text] [Related]
40. Current perspective on rituximab in rheumatic diseases.
Schioppo T; Ingegnoli F
Drug Des Devel Ther; 2017; 11():2891-2904. PubMed ID: 29042750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
